📰 Pascal Touchon News
Page 5 - Pascal Touchon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Touchon. Real-time updates on events, politics, business and more.
May 28, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 14,180,000 shares, a decrease of 20.3% from the April 30th total of 17,790,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio […]
May 28, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) saw a large decrease in short interest in May. As of May 15th, there was short interest totalling 14,180,000 shares, a decrease of 20.3% from the April 30th total of 17,790,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 10.0 days. […]
May 26, 2023
M28 Capital Management LP purchased a new position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 439,300 shares of the biotechnology company’s stock, valued at approximately $1,441,000. Atara Biotherapeutics makes […]
May 12, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has been given a consensus rating of “Hold” by the nine analysts that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average […]
May 10, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has earned a consensus recommendation of “Hold” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The […]
April 17, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has earned a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The […]
April 2, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 16,700,000 shares, a growth of 18.7% from the February 28th total of 14,070,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 13.1 days. […]
March 18, 2023
Analysts at StockNews.com started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. ATRA has been the subject of several other reports. Mizuho reissued a “buy” rating and set a $31.00 price target on shares of Atara […]
March 13, 2023
These companies are among the best and brightest in the immunotherapy field.
March 8, 2023
Lazard Asset Management LLC purchased a new position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,922 shares of the biotechnology company’s stock, valued at approximately $45,000. Several other institutional investors and hedge funds […]